Case 1 Male patient died while receiving semaglutide report invalidated because call-center contractors claimed patient identifier was missing (FDA found it in source documents) Case 2 Consumer taking liraglutide suffered a disabling stroke report cancelled because the consumer said it was unrelated to the drug Case 3 Patient taking semaglutide became depressed and committed suicide no follow-up attempts documented, still not submitted to FDA as of March 2026 Case 4 Consumer reported suicidal ideation on semaglutide in December 2024 not reviewed until February 2025, only after FDA inspectors flagged it Case 5 FDA found Novo Nordisk's written procedures allowed adverse events to be rejected based on causality assessments contradicting federal reporting requirements A Second Front: Vision Loss Claims Beyond the GI injury cases, a second GLP-1 MDL was created in December 2025 for vision loss claims
This article explains what triple agonist peptides are, how they differ from the single and dual agonist compounds that preceded them, what the term "GLP-3" refers to (and what it doesn't), and what Canadian researchers entering this category should understand before evaluating specific compounds
5 At one time, it was theorized that there was a single hormone responsible for this activity, but it was discovered that two hormones secreted from the intestines are primarily responsible for the incretin effect, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)
Do not use the medication if it looks cloudy, has particles, or is past the labeled beyond-use date
